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tions regarding surgical RCT’s in a lively format that will draw
examples several recently published or ongoing surgical trials.
Results: The randomized controlled trial (RCT) is the time-
honored scientiﬁc approach for assessing the efﬁcacy of inter-
ventions. Trial methodology has developed largely to conform to
the needs of pharmacologic studies. When RCTs are performed
in other settings, such as to assess the efﬁcacy of a surgical
intervention, investigators must confront difﬁcult methodological
questions. Some of these are unique to the non-pharmacological
setting and others are more challenging in this setting. For ex-
ample: what is an appropriate control in a trial of a surgical
intervention? Is sham surgery ethically defensible? To what ex-
tent can blinding can be achieved in the absence of a sham?
How does the research team ensure and assess compliance
with surgical or non surgical intervention? What are the scien-
tiﬁc consequences of cross-overs (from nonoperative therapy to
surgery, and vice versa) ? How can cross-overs be minimized
in the design of trials and accounted for in the trial analysis?
How should the investigator account for the effects of correlation
among patients of the same surgeon and the same hospital in
the design and analysis of trials?
Conclusions: This workshop will be of particular interest to
persons interested in non-pharmacological trials in OA, including
trials of surgery.
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The ongoing challenge of identifying valid molecular biomarkers
to monitor osteoarthritis (OA) has involved translating basic stud-
ies of joint tissue metabolism into reliable biochemical assays of
accessible body ﬂuid samples (i.e. synovial ﬂuid, serum, plasma,
urine) [1]. Predominantly, the aim of such assays is to survey the
turnover/release of macromolecules which may originate from
affected articular tissues (such as cartilage), and correlate these
levels with the degree of disease activity.
Practicable assays have been reported (and in many cases are
commercially available) for, among others, aggrecan degradation
products and substituents (i.e. glycosaminoglycans), type II col-
lagen fragments, cartilage oligomeric matrix protein (COMP) and
hyaluronan (HA). In addition, procedures to assay the neosynthe-
sis of aggrecan and collagens are described, and offer additional
measurements for combining multiple biomarker parameters in
attempts to enhance diagnostic accuracy [2-4].
Attention has also been directed toward the catabolism of small
leucine-rich proteoglycans (SLRPs) and the ability to quantify
relevant SLRP fragments in biomarker assays [5]. Other logical
candidates to assess may include the cartilage boundary glyco-
protein lubricin/PRG4 [6], and a variety of other proteinaceous
components which, for example, are differentially abundant in
normal and osteoarthritic human cartilage extracts [7].
While inherent variation among individuals poses signiﬁcant hur-
dles, the utility of using appropriate molecular biomarkers as
surrogate measures of OA offers promise for longitudinal as-
sessments, and in the evaluation of potential responses to ther-
apeutic, interventional treatments [8].
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Purpose: A number of factors increase the risk of osteoarthritis
including genetic predisposition, body mass, and developmental
disorders including joint dysplasias. However, in all populations,
age and excessive articular surface contact stress are asso-
ciated with substantial increases in the probability of the joint
degeneration that leads to the clinical syndrome of osteoarthritis.
With increasing age, articular cartilage loses tensile stiffness and
strength, frequently develops superﬁcial ﬁbrillation and alteration
of matrix macromolecules including proteoglycans and collagens.
We have been investigating the causes of these biological and
biomechanical age related changes in articular cartilage.
Methods: To examine the age related changes in human chon-
drocytes we have harvested articular cartilage samples from
humans ranging in age from newborns to the elderly. We have
studied the function of the chondrocytes in culture and in their
native matrix and tested their responses to mechanical stimuli
and antioxidants.
Results: We have found that with increasing age human chon-
drocytes show decreased synthetic activity, decreased prolifer-
ative activity, altered proteoglycan synthesis and a decline in
the response to anabolic growth factors. In addition, we have
found that with increasing age chondrocytes show a decline
in cartilage speciﬁc gene expression including aggrecan gene
expression and in their ability to form a cartilaginous matrix in
culture. In human chondrocytes these changes are associated
with a decrease in telomere length. Recent studies indicate that
loss of telomere length is a marker of impaired chondrocyte
function that is caused at least in part by cumulative oxidative
damage. We have also explored the role of chondrocyte ox-
idative damage in the development of osteoarthritis in young
adults and in particular the osteoarthritis that develops follow-
ing joint injuries (post-traumatic osteoarthritis) and in association
with joint dysplasia. In both of these conditions the articular sur-
face is exposed to increased contact stress. A study of human
articular cartilage in vitro shows that increased contact stress
and in particular shear stress increases the release the oxygen
free radicals. This increase in oxygen free radicals is associated
with chondrocyte death and apoptosis and use of antioxidants
blocks a substantial fraction of this deleterious effect. In addition,
we have found that pre-conditioning chondrocytes with oxidants
appears to stimulate antioxidant defenses and protects the cells
from mechanical stress induced apoptosis and death. Protect-
ing human chondrocytes from oxidative damage and providing
them with telomerase as a DNA repair mechanism substantially
